Product Description
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, _-Catenin, and TRK pathways (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33409897/)
Mechanisms of Action: AURKA Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Taiho
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TAS-119-102 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2019-08-01 |
|
| TO-TAS-119-101 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2018-07-01 |